Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acurx Pharmaceuticals, LLC*

0.4573
-0.1947-29.86%
Pre-market: 0.46960.0123+2.69%04:16 EDT
Volume:1.18M
Turnover:548.26K
Market Cap:8.91M
PE:-0.43
High:0.5000
Open:0.4605
Low:0.4500
Close:0.6520
Loading ...

BRIEF-Acurx Pharmaceuticals Announces $2.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
07 Jan

Acurx Launches $2.5 Million Registered Direct Offering; Shares Fall After-Hours

MT Newswires Live
·
07 Jan

Acurx to sell 2.46M shares at $1.015 in registered direct offering

TIPRANKS
·
07 Jan

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
07 Jan

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire
·
07 Jan

BRIEF-Acurx Receives Positive Regulatory Guidance From EMA For Ibezapolstat Phase 3 Program For CDI

Reuters
·
06 Jan

Acurx Receives Positive Regulatory Guidance From Ema for Ibezapolstat Phase 3 Program for C. Difficile Infection (Cdi)

THOMSON REUTERS
·
06 Jan

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

PR Newswire
·
06 Jan

Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?

Zacks
·
03 Jan

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

ACCESSWIRE
·
12 Dec 2024

Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

BRIEF-FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3

Reuters
·
09 Dec 2024

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile Infection Based on Recent FDA and Ema Communications

THOMSON REUTERS
·
09 Dec 2024

Acurx Pharmaceuticals Inc - FDA Provides Positive Feedback on Acurx's Cmc Plan for Phase 3

THOMSON REUTERS
·
09 Dec 2024

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

PR Newswire
·
09 Dec 2024

Trump's crypto advocacy steers businesses away from traditional treasury assets

Reuters
·
05 Dec 2024